Abliva AB represents values of innovation, integrity, and commitment to improving patients' lives. With a corporate philosophy centered around scientific excellence, Abliva aims to develop effective treatments for rare mitochondrial disorders and other genetic diseases. By harnessing its expertise in mitochondrial medicine and drug development, the company strives to bring forth novel therapies that address unmet medical needs. Abliva AB's dedication to collaboration and cutting-edge research further fuels its mission, enabling the advancement of potential breakthrough treatments. Through its focus on improving patient outcomes and pushing the boundaries of medical innovation, Abliva AB demonstrates a strong commitment to making a positive impact in the field of medicine.

Abliva AB is primarily present in Sweden, with its headquarters located in Stockholm. As a biopharmaceutical company, Abliva AB focuses on the research and development of treatments for rare mitochondrial diseases. With a strong presence in the Swedish healthcare industry, Abliva AB aims to improve the quality of life for patients suffering from these conditions.

Abliva AB has achieved several significant milestones in its journey. Notable achievements include the successful completion of Phase IIa clinical trial of KL1333, a potential treatment for mitochondrial diseases. The company also received Orphan Drug Designation for KL1333 from the U.S. FDA and the European Medicines Agency, recognizing its potential in addressing unmet medical needs. Furthermore, Abliva AB has forged collaborative partnerships with renowned institutions like Massachusetts General Hospital and The Feinstein Institutes for Medical Research, enhancing its research and development capabilities. These milestones demonstrate Abliva AB's commitment to advancing breakthrough therapies for mitochondrial disorders and underline its position as a leading player in the field.

Abliva AB is a biopharmaceutical company based in Sweden. It was founded in 2016 and is focused on developing treatments for rare mitochondrial diseases. The company's mission is to improve the lives of patients with these challenging conditions by advancing innovative therapies. Abliva AB combines cutting-edge science with a deep understanding of mitochondrial biology to identify potential drug candidates. With a dedicated team of experts, Abliva AB continues to research and develop promising treatments to address unmet medical needs in the field of mitochondrial diseases. Abliva AB is committed to making a positive impact on patients' lives and transforming the landscape of mitochondrial medicine.

Abliva AB faces competition from various companies in the market, including XYZ Corporation, ABC Inc., and DEF Ltd.

Abliva AB is primarily active in the pharmaceutical and biotechnology industries.

The business model of Abliva AB is focused on the development and commercialization of innovative treatments for rare mitochondrial diseases. Abliva AB aims to address the unmet medical needs of patients by developing effective therapies that target the underlying causes of these debilitating conditions. The company's business strategy revolves around identifying potential drug candidates, conducting preclinical and clinical studies, seeking regulatory approvals, and ultimately bringing its products to market. By leveraging its expertise in mitochondrial medicine, Abliva AB aims to improve the lives of patients affected by rare mitochondrial diseases through the development of novel and targeted therapies.

Коефициентът на цена спрямо печалбата (КЦП) на Abliva е -1,36.

Коефициентът на цена към оборот (KUV) на Abliva е 0.

AlleAktien качественият резултат за Abliva е 2/10.

Приходите не могат да бъдат изчислени в момента за Abliva.

очаквана Abliva печалба е -131,53 млн. SEK.

Abliva AB is a biopharmaceutical company based in Stockholm, Sweden. The company specializes in the development of therapeutics for the treatment of rare diseases. Abliva AB has three main business areas: Neurology, Mitochondrial Diseases, and other rare diseases. The company has several product candidates in the pipeline targeting various disease areas. One of Abliva AB's key product candidates is KL1333, an oral medication for the treatment of primary mitochondrial myopathy (PMM). PMM is a rare disease that affects muscle function and typically occurs early in life. KL1333 is currently in Phase IIb clinical trials and has the potential to be an important treatment option for patients with PMM. Another important product candidate of Abliva AB is NV354, an oral medication for the treatment of epilepsy and other neurological disorders. NV354 is currently in the preclinical phase and shows promising results in animal models. Abliva AB is also working on developing therapeutics for the treatment of other rare diseases such as liver diseases and metabolic disorders. The company has a strong pipeline of product candidates expected to be brought to market in the coming years. Abliva AB's business model is based on partnerships with other pharmaceutical companies and investors to finance and accelerate the development of its product candidates. Abliva AB collaborates closely with leading scientists and researchers to develop innovative therapeutics for the treatment of rare diseases. Abliva AB also has strong intellectual property and patents its technologies and product candidates, which helps strengthen its competitive position and ensure the protection of its products in the market. Overall, Abliva AB aims to play a significant role in the development of therapeutics for the treatment of rare diseases. The company has a strong pipeline of product candidates and works closely with other companies and investors to finance and advance the development of its products. With its strong intellectual property and innovative research, Abliva AB has the potential to play a key role in the treatment of rare diseases and improve the lives of affected patients.

Abliva разпределя дивидента от 0 SEK на плащания годишно.

Дивидентата за Abliva в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Abliva е SE0002575340.

WKN на Abliva е A0X93Z.

Тикерът на Abliva е ABLI.ST.

През последните 12 месеца Abliva изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Abliva да изплати дивиденда в размер на 0 SEK.

Дивидентната доходност на Abliva в момента е .

Abliva изплаща дивидент на тримесечие. Той се разпределя в месеците .

Abliva платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 SEK. Това съответства на дивидентна доходност от 0 %.

Abliva се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Abliva на 29.09.2024 г. в размер на 0 SEK, трябваше да притежавате акцията в портфейла си преди Ex-деня на 29.09.2024 г..

Последното дивидентно плащане беше извършено на 29.09.2024 г..

През година 2023 Abliva изплати 0 SEK под формата на дивиденти.

Дивидентите от Abliva се изплащат в SEK.